Search
Highlights from the SWG
SWG AML Annual Scientific MeetingThe most recent SWG AML Annual Scientific Meeting took place during the annual EHA Congress in Frankfurt, Germany.
Read moreEHA-GBMTA-AHA Hematology Tutorial
EHA is joining the Georgian Association for Blood and Bone Marrow Transplantation (GBMTA) and Armenian Hematology Association (AHA) to organize the EHA-GBMTA-AHA Hematology Tutorial on New Aspects in Diagnostic Choices and Treatment Options of Hematological Malignancies.
Read moreExpert opinions for COVID-19 vaccination in patients with hematologic cancer
Ronja Brockhoff, Hamdi Akan, Rafael Duarte, Martin Hönigl, Nikolay Klimko, Sibylle C. Mellinghoff, Livio Pagano, Antonio Pagliuca, Paul Verweij, Oliver A.
Read moreFirst CMML guidelines produced by EHA, now available
Chronic myelomonocytic leukemia (CMML) is a rare disease with overlapping features of two categories of bone marrow and blood cell disorders that poses challenges in clinical management.
Read moreEHA-Balkan Hematology Tutorial on Lymphoid Malignancies
“EHA and the Albanian Association of Hematology have jointly decided to postpone the first EHA-Balkan Hematology Tutorial in response to a request from the Albanian government to limit all international meetings.
Read moreIn Memoriam Pieter Van Vlierberghe
We are deeply saddened to announce that Pieter Van Vlierberghe (42) has passed away.
Stopping tyrosine kinase inhibitors in a very large cohort of European chronic myeloid leukemia patients: results of the EURO-SKI trial
Tyrosine kinase inhibitors (TKI) have substantially improved survival in patients with chronic myeloid leukemia in chronic phase. However, treatment is in clinical practice considered life-long.
Read moreEuropean Hematologists will discuss breakthroughs in blood disorders in Milan, Italy - June 12-15, 2014
About the EHA Annual Congress
Hematology is a specialty that covers everything to do with blood: its origin in the bone marrow, diseases of blood and their treatments.
Targeting the B-cell Receptor in Aggressive B-cell Lymphomas
In collaboration with Dr. Lou Staudt, Pharmacyclics and associate investigators, we performed a clinical trial of a very potent inhibitor of Bruton Tyrosine Kinase (BTK) called ibrutinib.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- »